IGF‑1 DES is a truncated form of IGF‑1 with reduced binding to IGF‑binding proteins and a roughly 20‑minute half‑life, and it is being used off‑label by the community to promote muscle growth and localized intramuscular hypertrophy. The most common self‑reported regimen is 50 µg per day, although users have experimented up to 1 mg daily, and most do not specify timing or cycling. The primary limitation is that the off‑label evidence base is thin, with few published results, and injection‑site reactions have not emerged as a consistent theme.
Data last updated
Measured on 5 of 6 axes
Evidence shape
No CT.gov-registered trials for IGF-1 DES, but 1 published human study was extracted from the literature — peer-reviewed reports below, split into treatment vs diagnostic/mechanistic, not registry-grade evidence. Off-label / exploratory data exists for 1 additional indication (Diagnostic & mechanistic studies).
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Diagnostic & mechanistic studies
1 study
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How IGF-1 DES is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
According to the available data, no completed trial has been identified for this tier, so dosing cannot be reliably extracted.
Clinician protocols dose 75 µg daily IM (1 source).
Users report intramuscular doses ranging from 50 mcg to 1 mg, with one taking 1 mg daily and another using 50‑150 mcg at an unspecified frequency.